PMGC HOLDINGS INC. Business Acquisition, Pro Forma Revenue
PMGC HOLDINGS INC. (ELAB) reported Business Acquisition, Pro Forma Revenue of $1.71 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2024-03-29
- PMGC HOLDINGS INC. business acquisition, pro forma revenue for fiscal 2023 was $1.71M.
| Period end | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|
| 2023-12-31 | $1.71M 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B |